Detailed instructions and patient medication guide for Eltrombopag (Revlan)

1. Drug introduction and mechanism of action

Eltrombopag is an oral thrombopoietic agent, commonly known as Revolade or Promacta. It belongs to the thrombopoietin receptor agonist (TPO-RA) class of drugs. Its main mechanism of action is to bind to the thrombopoietin receptor (TPO-R, also known as c-Mplreceptor) to stimulate the proliferation and differentiation of megakaryocytes in the bone marrow, thereby promoting platelet production and increasing the number of peripheral platelets. This drug is commonly used to treat patients with chronic immune thrombocytopenia (ITP), severe aplastic anemia (SAA) and chronic hepatitis C with thrombocytopenia. Eltrombopag is a small molecule drug with good oral bioavailability, significant efficacy and high safety. It is one of the platelet-raising drugs widely used in clinical practice.

2. Indications and scope of medication

Eltrombopag is mainly suitable for three major groups of people:

1.Patients with chronic immune thrombocytopenia (ITP) - suitable for adult or pediatric patients who have an inadequate response to glucocorticoids, immune globulin or splenectomy;

2.Chronic hepatitis C-related thrombocytopenia—used to increase platelet levels before antiviral treatment so that patients can safely receive interferon therapy;

3.Patients with severe aplastic anemia (SAA) - suitable for patients who are unresponsive or relapsed to immunosuppressive therapy to stimulate hematopoietic recovery.

In addition, some studies have also explored its potential application in chemotherapy-related thrombocytopenia and myelosuppressive diseases. However, these uses have not been officially approved and should be used with caution under the guidance of a doctor.

3. Usage, dosage and medication guidance

Eltrombopag is an oral preparation, with three common specifications: 25mg, 50mg and 75mg. The specific dose needs to be adjusted individually based on the patient's age, condition and platelet level:

1.For adult ITP patients, the recommended starting dose is 50mgonce daily;

2.For East Asian patients (including Chinese), due to differences in drug metabolism, the starting dose is generally recommended to be25mgonce a day;

3.For patients with severe aplastic anemia, the initial dose can be50mgonce a day, gradually increasing or decreasing according to the response;

4.For patients with chronic hepatitis C, the starting dose is25mgonce a day.

The medication should be taken on an empty stomach, that is, 1 hour before meals or 2 hours after meals to avoid binding with metal ions (such as calcium, iron, magnesium) in food and affecting absorption. If it must be taken with food, foods or drugs containing polyvalent cations such as dairy products, calcium tablets or iron supplements should be avoided.

4. Curative effect observation and monitoring indicators

After taking eltrombopag, patients can generally observe a gradual increase in platelet count within 1 to 2 weeks, and enter a stable phase after 3 to 4 weeks. Doctors usually monitor the platelet count once a week in the early stages of treatment and adjust the dose based on the results to maintain platelets at a safe level (usually 50×10⁹/ L to 150×10⁹/L) to prevent bleeding without increasing the risk of blood clots.

In addition to platelet monitoring, liver function (ALT, AST, bilirubin) should also be tested regularly, because eltrombopag may cause mild elevation of liver enzymes during liver metabolism. Patients with long-term use should also monitor serum ferritin, bone marrow imaging and retinal examination to prevent potential adverse reactions.

5. Adverse reactions and countermeasures

Eltrombopag is generally well tolerated, but the following side effects may still occur:

1.Abnormal liver function: manifested as elevated transaminases or jaundice. Liver enzyme levels should be monitored regularly if they exceed the upper limit of normal3It is necessary to consider suspending the medication.

2.Increased risk of thrombosis: When platelets rise too fast or too high (>400×10⁹/L), the possibility of thrombotic events may increase, and the dose should be adjusted in time.

3. Mild reactions such as headache, fatigue, joint pain, and nausea: most are transient and can be relieved by themselves.

4.Risk of myelofibrosis: Long-term medication may stimulate myelofibrosis, and bone marrow conditions should be checked regularly under the guidance of a doctor.

If severe discomfort occurs or liver function deteriorates significantly, the drug should be discontinued immediately and seek medical treatment.

6. Drug interactions and precautions

Taking eltrombopag together with drugs containing metal ions (such as calcium, iron, magnesium preparations) will reduce absorption, and should be used at least 4 hours apart. When combined with antiviral drugs such as interferon and ribavirin, it is necessary to monitor platelet fluctuations to prevent sudden thrombosis. In addition, pregnant and lactating women should be cautious when using the drug, as there is currently insufficient clinical safety data to support its use. Patients with moderately to severely impaired liver function or a history of high risk of thrombosis should be used under strict supervision.

7. Medication discontinuation and treatment course management

Eltrombopag is a long-term conditioning medication, and the platelet count will usually return to the pre-treatment level within 2 weeks after stopping the drug. Therefore, the risk of bleeding should be closely monitored during drug withdrawal or dose reduction. If the platelet count drops below the safe lower limit, medication should be re-evaluated under the guidance of a doctor. Some patients can gradually reduce the dosage or take medication intermittently after stable treatment to balance efficacy and safety.

8. Patient life management and dietary suggestions

During medication, patients are advised to maintain a regular schedule and avoid strenuous exercise and trauma to reduce the risk of bleeding. High-fat, spicy and alcoholic foods should be avoided in the diet to reduce the burden on the liver. Supplementing more protein and foods rich in vitamin C can help blood production and immune regulation.

Eltrombopag is a safe and effective pro-thrombopoietic drug, bringing new treatment options to patients with a variety of thrombocytopenic diseases. Patients should strictly abide by the doctor's instructions, regularly review platelet and liver function, and rationally adjust the dosage to ensure maximum efficacy and minimize risks. Scientific medication and regular monitoring are the keys to ensuring successful treatment.

Reference materials:https://www.drugs.com/